Brief: Theranexus H1 Net Operating Loss Narrows To EUR 3.4 Million
29/09/2020 17:00
Sept 29 (Reuters) - THERANEXUS ALTHX.PA :
* H1 NET OPERATING LOSS NARROWED TO EUR 3.4 MILLION
* H1 NET LOSSES WERE EUR 2.9 MILLION
* H1 OPERATING INCOME EUR 271,000 VERSUS EUR 574,000 YEAR AGO
* ON 30 JUNE 2020, TOTAL AVAILABLE FUNDS STOOD AT EUR 11.3 MILLION AND PRO FORMA CASH AT EUR
13.3
MILLION
Source text for Eikon: ID:nACT65294
Further company coverage: ALTHX.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Thx Pharma SA
See all newsBrief: Theranexus And BBDF Announce Final And Positive Safety And Efficacy Data In The Phase I/II Trial Testing Batten-1
Brief: Theranexus End-Dec Total Available Funds Stood At EUR 4.9 Mln
Brief: Theranexus Declares Encouraging Prelim Results For Batten Disease Drug
Brief: Theranexus And BBDF Granted Positive Opinion By EMA For Design Of Batten-1 Phase III Trial
Brief: Theranexus And BBDF Win FDA Approval On Endpoints For Phase III Trial To Evaluate Batten-1 In CLN3 Batten Disease